Telomir Pharmaceuticals Reports Promising Progeria Study Results

Telomir Pharmaceuticals, Inc. announced noteworthy findings from a preclinical study on progeria, conducted in collaboration with Nagi Bioscience SA. The study involved C. elegans nematode models with a wrn-1 gene mutation. This mutation is linked to Werner Syndrome in humans, a form of progeria causing rapid aging. Results showed lifespan restoration and normalization in these models when treated with Telomir-1, aligning their longevity with normal nematodes.

Telomir-1 is designed to address cellular dysfunction by managing metal activity within the body, reducing oxidative stress and inflammation. These mechanisms potentially protect against conditions like Wilson’s disease and Type 2 diabetes.

Further, the company is preparing in vitro studies on human progeria cell lines to substantiate Telomir-1’s efficacy in cellular health restoration. However, Telomir-1 remains in preclinical development with no human testing or FDA approval yet.